Cancers, Vol. 13, Pages 5291: Network-Based Analysis to Identify Drivers of Metastatic Prostate Cancer Using GoNetic

Cancers, Vol. 13, Pages 5291: Network-Based Analysis to Identify Drivers of Metastatic Prostate Cancer Using GoNetic Cancers doi: 10.3390/cancers13215291 Authors: Louise de Schaetzen van Brienen Giles Miclotte Maarten Larmuseau Jimmy Van den Eynden Kathleen Marchal Most known driver genes of metastatic prostate cancer are frequently mutated. To dig into the long tail of rarely mutated drivers, we performed network-based driver identification on the Hartwig Medical Foundation metastatic prostate cancer data set (HMF cohort). Hereto, we developed GoNetic, a method based on probabilistic pathfinding, to identify recurrently mutated subnetworks. In contrast to most state-of-the-art network-based methods, GoNetic can leverage sample-specific mutational information and the weights of the underlying prior network. When applied to the HMF cohort, GoNetic successfully recovered known primary and metastatic drivers of prostate cancer that are frequently mutated in the HMF cohort (TP53, RB1, and CTNNB1). In addition, the identified subnetworks contain frequently mutated genes, reflect processes related to metastatic prostate cancer, and contain rarely mutated driver candidates. To further validate these rarely mutated genes, we assessed whether the identified genes were more mutated in metastatic than in primary samples using an independent cohort. Then we evaluated their association with tumor evolution and with the lymph node status of the patients. This resulted in fo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research

Related Links:

Men with localized prostate cancer who opt for surgery instead of surveillance are more than twice as likely to regret their decision.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
RefleXion Medical's biology-guided radiotherapy has received a breakthroug...Read more on AuntMinnie.comRelated Reading: RefleXion to showcase tech, abstracts at ASTRO 2021 Lantheus, RefleXion to collaborate on prostate cancer treatment RefleXion to install X1 at cancer center in Texas RefleXion raises another $40M, mulls Asia strategy RefleXion, Telix partner on high-risk cancer treatments
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Condition:   Prostate Cancer Interventions:   Drug: LY01005;   Drug: ZOLADEX® 3.6 mg Sponsor:   Luye Pharma Group Ltd. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Brief Bioinform. 2021 Nov 27:bbab465. doi: 10.1093/bib/bbab465. Online ahead of print.ABSTRACTProstate cancer is the second leading cause of cancer-related death in men. Metastasis shows poor survival even though the recovery rate is high. In spite of numerous studies regarding prostate carcinoma, multiple questions are still unanswered. In this regards, gene regulatory network can uncover the mechanisms behind cancer progression, and metastasis. Under a feed forward loop, transcription factors (TFs) can be a good druggable candidate. We have proposed a computational model to study the uncertainty of TFs and suggest the ap...
Source: Briefings in Bioinformatics - Category: Bioinformatics Authors: Source Type: research
The objective of this study was to identify differentially expressed microRNAs in these cell lines, which may be responsible for the EMT phenotype. Unsupervised hierarchical clustering confirmed that microRNA expression profiles are distinctly different between the two cell lines, with 119 miRNAs significantly increased and 81 microRNAs significantly decreased in ARCaPM cells as compared to ARCaPE. Further analysis revealed that many of the differentially expressed microRNAs belong to only a few microRNA families/clusters. Unsurprisingly, microRNAs in these clusters are co-expressed due to common promoters, which are known...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Zeynep Madak-Erdogan ; Ozan B Imir ; Qianying Zuo ; Yu-Jeh LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPer- and polyfluoroalkyl substances (PFAS) are synthetic chemicals utilized in various industrial settings, and include products such as flame retardants, artificial film-forming foams, cosmetics, non-stick cookware among others. Epidemiological studies suggest a link between increased blood PFAS levels and prostate cancer incidence, but the mechanism through which PFAS impact cancer development is unclear. To investigate the link between PFAS and prostate cance...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone'preferred'initial treatment option.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Prostate Cancer and Prostatic Diseases, Published online: 01 December 2021; doi:10.1038/s41391-021-00473-7Instagram and prostate cancer: using validated instruments to assess the quality of information on social media
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
Despite significant advances in therapeutic developments for prostate cancer over the last 2 decades, metastatic prostate cancer remains a lethal disease. Prostate-specific membrane antigen (PSMA), which is markedly overexpressed in prostate cancer cells and metastatic sites but has low normal-tissue expression, has emerged as an important theranostic target for this disease. Both β-emitting and α-emitting PSMA-targeted radionuclide therapy (RNT) are in clinical development. Several of these agents have already shown promising activity; however, a subset of patients have primary resistant disease, and secondary ...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: The State of the Art Source Type: research
Conclusion: 18F-rhPSMA-7.3 PET offered high detection efficacy in patients with biochemical recurrence after radical prostatectomy and before potential salvage therapy and resulted in a potential change in treatment plan in nearly two thirds of patients.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Investigations Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Prostate Cancer